Abstract PD5-06: Prognostic value of molecular tumor infiltrating lymphocyte (mTIL) signatures in HER2-positive breast cancer patients in N9831 and FinHer/FinXX trials

Saranya Chumsri, E. Aubrey Thompson, Afshin Mashadi-Hossein et al.|Cancer Research|2017

Cited by 0